Table 1.
Clinical characteristics of the surviving and non-surviving patients with COVID-19 infection.
| VARIABLE | |
|---|---|
| Total | N = 40 |
| Age | 63 ± 18 |
| Male (%) | 56% |
| BMI | 29.4 ± 6 |
| Comorbidities % | |
| Diabetes (%) | 42 |
| Hypertension (%) | 53 |
| Lung disease (%) | 7 |
| Hemodialysis (%) | 0 |
| Aspirin use (%) | 50 |
|
Symptom’s duration before admission to hospitals
(days) |
6 ± 4 |
|
Symptoms before admission
(% of total) |
|
| Fever % | 61 |
| Diarrhea % | 0 |
| Dyspnea % | 58 |
| Clinical severity upon admission % | 23 |
| Lab Findings upon admission | |
| Hemoglobin (mg/dL) | 12.5 ± 1.5 |
| Absolute neutrophil count (×103/µL) | 4.4 ± 2.6 |
| Absolute lymphocyte count (×103/µL) | 1.07 ± 0.7 |
| Neutrophil to lymphocyte ratio (NLR) | 5.7 ± 4.7 |
| Platelet (×103/µL) | 190 ± 92 |
| BUN (mg/dL) | 17.5 ± 8.8 |
| Creatinine (mg/dL) | 1.01 ± 1.0 |
| Triglycerides (mg/dL) | 140 ± 57 |
| HDL (mg/dL) | 28 ± 10 |
| C-reactive protein (CRP) (mg/dL) | 99 ± 86 |
| Ferritin (µg/L | 466 ± 325 |
| D-dimer (ng/mL) | 1080 ± 813 |
| Fibrinogen (mg/dl) | 677 ± 165 |
| ALT (U/L) | 24 ± 16 |
| 4-C score | 7.0 ± 4.5 |
| O2 supplement upon admission % | 11 |
| High flow use (% of total) | 11 |
| Survival (% of total) | 85 |
Abbreviation: BMI: Body mass index, ALT: Alanine transaminase.